Join PainCast

Do you want to know more about Pain Medicine? Join PainCast to view hundreds of exclusive videos, and access to luminary physicians, forums, and more!

Coronavirus Update: My Grandson’s Recovery with use of Camostat Mesylate

Gabor B Racz on April 10, 2020 at 4:03 pm
  • Author
    • Gabor B RaczGabor B Racz
      Joined: Mar 28, 2016
      Posts: 30

      Full-Blown Respiratory Changes, possibly due to Coronavirus, with Recovery with use of Camostat Mesylate. Proposed Mechanism in the Lung, similar to that of the Pancreas.
      April 2020
      Gabor B. RaczGabor B. Racz

      Dear Sirs or Madames,

      Please consider adding these comments regarding unusual circumstances about severe coronavirus cases. This happened recently, and may be relevant. We’ve been in social isolation for over three weeks in the mountains of NM, with my wife of 80 years old and my very gifted grandson, Nicholas Racz, who, from all his readings, noticed the mechanism of action of Coronavirus, SARS1, in an older research article denoting the ACE2 receptor site as the entry point for Coronavirus into cells.( .) Seeing that SARS2 has similar phylogeny and form he found a follow up article from CELL lending credence to these hints( A specific drug was found to inhibit this without cytotoxicity, and it was reasonable to suggest that the pulmonary site of Coronavirus infection had the same active receptor of Pancreatitis, ACE2. After discussions of these discoveries, three weeks later he received two packages of Camostat Mesylate from a Japanese Pharmacist. Two days later, my colleague, returning after extensive travel on family vacation, suddenly felt very sick, lethargic, with a progressively pernicious dry cough. She was getting worse, being in a high-risk group, with a fever of 104F and coexistent disease. When the news of her severe respiratory problem got to us, after discussion, reviewing the human data with full informed patient-consent, and based on the dosages used for pancreatitis with no cytotoxicity, we overnight mailed it to my colleague if used, 200mg TID. After taking the Camostat, she made a dramatic turnaround, with said fever knocked down to 99F and immediate respiratory relief. The dry cough became a moist cough, with the subsequent few days showing dramatic recovery. Extended use of the antimalarial medication, Hydroxycholoroquine, along with FDA approval, was unknown to us at this time. Ten days ago, my art student grandson, living in New York, came down with similar symptoms. By the time he reached the emergency room he had: • Dry cough • High fever • Sore throat • Respiratory symptoms I suggested, on first hearing the symptoms, on Zithromycin, in the form of Z-pack, but he progressed on a similar course, necessitating a visit to the emergency room due to a feeling of suffocation. Following a discussion with my physician son, his father, the second and final pack of Camostat Mesylate was overnight mailed to New York City. The same dose pattern was recommended if used, 200mg TID. He proceeded to see a lower temperature, improved respiration, and general well-being as one would expect for a young man. Five days later, he is feeling fine. These two patients follow the same course, one of high-risk group, the other not. In conjunction with the Camostat Mesylate: (For the high-risk patient) • NAC • L-Arginine • Camostat Mesylate (For my grandson) • NAC • Camostat Mesylate Having seen these two cases, I felt it is worthwhile to share with interested colleagues. The potential usefulness for severe respiratory complication of the possible Coronavirus infection is here. Only two cases, but 2 out of 2 is 100%.

      Sincerely, Gabor Racz MD ABIPP FIPP Grover Murray Professor Past President WIP

      • Robert RapcanRobert Rapcan
        Joined: Dec 6, 2018
        Posts: 7

        Very interesting clinical experience. 2 patients with 100% clinical improvement. I have seen this regarding the topic before:

        Investigators in Germany took a step toward determining a potential novel therapeutic intervention for COVID-19 after identifying a cellular protein that may allow entry of SARS-CoV-2 into lung cells.

        The research, published in the journal Cell, examined how SARS-CoV-2 enters human cells and found that a drug currently approved in Japan to treat pancreatic inflammation could block the COVID-19 infection.

        “Our results show that SARS-CoV-2 requires the protease TMPRSS2, which is present in the human body, to enter cells,” Stefan Pöhlmann, head of the Infection Biology Unit at the German Primate Center, said in a statement. “This protease is a potential target for therapeutic intervention.”

        The research team was led by infection biologists from the German Primate Centre and included investigators from Charité, the University of Veterinary Medicine Hannover Foundation, the BG-Unfallklinik Murnau, the LMU Munich, the Robert Koch Institute and the German Center for Infection Research.

        The novel coronavirus is closely related to SARS-CoV, which emerged in 2002 and was stopped with measures including travel restrictions and patient isolation. The new study compared the 2 viruses and found similar properties and pandemic potential. Investigators noted that the spike protein (S protein) of the coronaviruses facilitates attachment to human cells through a 2-step process. SARS-CoV-2 depends on angiotensin-converting enzyme 2 (ACE2) for entry and serine protease TMPRSS2 for S protein priming. The study also determined that antibody responses raised by the earlier SARS-CoV could potentially provide partial protection against the novel virus, which may help control the outbreak.

        Better understanding of the transmissibility and pathogenesis of SARS-CoV-2 brought investigators closer to a possible therapeutic intervention.

        “We have tested SARS-CoV-2 isolated from a patient and found that camostat mesilate blocks entry of the virus into lung cells,” lead author Markus Hoffmann, PhD, a researcher at the German Primate Center, said in the statement. “Our results suggest that camostat mesilate might also protect against COVID-19. This should be investigated in clinical trials.”

        Camostat mesilate is approved in Japan to treat pancreatic inflammation.

        The study demonstrated that the drug blocked infection of human lung epithelial cells in culture. Human trials are necessary to prove whether the drug would be effective in stopping the infection.

        Here in Slovakia the situation stable, only 2 peaple past away.

        • Gabor B RaczGabor B Racz
          Joined: Mar 28, 2016
          Posts: 30

          Dear Robert,

          Thank you for the information. I’m not at all surprised. I still remember Bartfa and how beautiful the town is. That Queen Elizabeth chose it for repeated annual visits is obvious once you have been there. I have spoken to couple people about you, saying what a fine doctor you have become. Just for your information, we are on a New Mexican lake, seven thousand feet altitude, looking at twelve thousand foot snow capped mountains. Our county only has 1 confirmed case of coronavirus. You probably will say that the county of Bartov has 0, but hammer has been thrown down for you.

          Feel free to call me, great to hear from you.


          PS: Reviewing the record, it shows that you are now up to three deaths in the great state of Slovakia/Northern Hungary.

        Viewing 2 reply threads

        Join The Discussion

        Reply To: Coronavirus Update: My Grandson’s Recovery with use of Camostat Mesylate
        Your information:

        <a href="" title="" rel="" target=""> <blockquote cite=""> <code> <pre class=""> <em> <strong> <del datetime="" cite=""> <ins datetime="" cite=""> <ul> <ol start=""> <li> <img src="" border="" alt="" height="" width="">

        Comments are closed.